| 生物制剂治疗天疱疮与大疱性类天疱疮 |
| |
| 引用本文： | 铁&#,杜尔娜,左亚刚.生物制剂治疗天疱疮与大疱性类天疱疮[J].国际皮肤性病学杂志,2014,40(1):66-69. |
| |
| 作者姓名： | 铁&# 杜尔娜 左亚刚 |
| |
| 作者单位： | 铁·杜尔娜 (中国医学科学院北京协和医学院北京协和医院皮肤科,北京,100730)； 左亚刚 (中国医学科学院北京协和医学院北京协和医院皮肤科,北京,100730)； |
| |
| 基金项目： | 国家自然科学基金(项目编号：81071301),北京市自然科学基金(项目编号：7132203) |
| |
| 摘 要： | 研究显示，生物制剂治疗难治性天疱疮、类天疱疮疗效显著，其中利妥昔是一种源自基因工程的人鼠嵌合型抗B淋巴细胞CD20的单克隆抗体，最早应用于天疱疮和类天疱疮的治疗。除利妥昔外，p38丝裂原活化蛋白激酶抑制剂KC706、PI-0824疫苗、肿瘤坏死因子拮抗剂或单克隆抗体如英夫利西等均取得满意疗效。但应用生物制剂治疗天疱疮和类天疱疮存在严重不良反应的可能性，且价格昂贵、缺乏一定量的可靠临床疗效的数据，影响了生物制剂在临床中的广泛应用。
|
| 关 键 词： | 天疱疮 类天疱疮 大疱性 生物制品 治疗 |
Application of biological agents in pemphigus and buHous pemphigoid |
| |
| Tie . Duema,Zuo Yagang.Application of biological agents in pemphigus and buHous pemphigoid[J].International Journal of Dermatology and Venereology,2014,40(1):66-69. |
| |
| Authors: | Tie Duema Zuo Yagang |
| |
| Institution: | . Department of Dermatology, Peking Union Medical College Hospital, Chinese Academy of Medical Sciences and Peking Union Medical College, Beifing 100730, China |
| |
| Abstract: | Recent studies have shown that biological agents are evidently effective for the treatment of refractory pemphigus and pemphigoid. Rituximab, a monoclonal human/mouse chimeric IgG1 antibody targeting the B-cell specific cell-surface antigen CD20, is the earliest and most widely used biological agent for pemphigus and pemphigoid. Besides rituximab, other agents such as infliximab, P38 mitogen activated protein kinase （MAPK） inhibitor KC706, PI-0824 vaccine and blockers of or monoclonal antibodies against tumor necrosis factor also have exhibited favorable effects. However, potentially serious adverse reactions, high expense and lack of reliable clinical data have limited the wide application of biological agents in the treatment of pemphigus and pemphigoid. |
| |
| Keywords: | Pemphigus Pemphigoid bullous Biological products Therapy |
| 本文献已被 维普 等数据库收录！ |
|
